Live Breaking News & Updates on Karst Peak

Stay updated with breaking news from Karst peak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

New fund targets companies battered by market doubts

Record low biotech valuations have prompted a new VC investor to start shopping with a planned $200 million fund. ....

Lou Panaccio , Patrick Davies , Chris Behrenbruch , Glenn Haifer , Telix Pharmaceuticals , Neuren Pharmaceuticals , Genera Biosystems , Karst Peak , Avita Medical ,

Twiggy-backed CurveBeam AI opens books for $154m float

Twiggy-backed CurveBeam AI opens books for $154m float
afr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afr.com Daily Mail and Mail on Sunday newspapers.

Lister Brian Flannery , Bell Potter , Melbourne University , Lodge Corporate , Andrew Forrest , Rich Lister Brian Flannery , Frazis Capital , Karst Peak Capital , Karst Peak ,

CurveBeam AI: Brian Flannery-backed medical imaging company CurveBeam AI kicks off $15m pre-IPO led by Bell Potter and Lodge Corporate

Brian Flannery-backed bone fragility imaging tech company CurveBeam AI is tapping investors for $15 million ahead of a 2023 float. ....

New York , United States , Greg Brown , Curvebeam Hirise , Stryker Corporation , University Of Melbourne , Drug Administration , Karst Peak , Hashan De Silva , Peak Capital , New York Stock Exchange Listed ,

Local AI start-up StraxCorp merges with US imaging tech player CurveBeam ahead of ASX IPO

Brian Flannery-backed bone fragility imaging tech company StraxCorp is merging with US CT imaging disrupter CurveBeam and kick-starting a pre-IPO raise. ....

Greg Brown , Bell Potter , Lister Brian Flannery Ilwella , Barun Singh , University Of Melbourne , Drug Administration , Lodge Corporate , Australian Financial Review , Australian Unity , Karst Peak , Rich Lister Brian Flannery , Acorn Capital ,

Why Neuren Pharmaceuticals is Karst Peak and Milford Asset Management's top biotech pick

Neuren Pharmaceuticals’ share price has almost doubled in six months, but investors think it’s still undervalued as it approaches its first FDA approval. ....

New South Wales , Jon Pilcher , Pitt Hopkins , Auckland University , Drug Administration , Us Army , Karst Peak Capital , Karst Peak , Milford Asset Management , Will Curtayne ,